PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Spideyboy thanks for the detailed answer.The middle of the year is the problem of my English . I meant during the year, that is, when a person started on one medicine and, say, in the second half of the year, changed it to the another.The 2 mg/kg administered every four weeks regimen is very important IMO because it can add a significant number of new patients. let's say family working man 25-35 years old doing well on the Fabrazyme.IMO, it is very tempting for him to reduce the number of infusions by half with the same drug efficacy to be more free and flexible.
Perhaps you have noticed this information.
At month 12, the mean slopes for eGFR were -2.507 mL/min/1.73 m²/year for the
pegunigalsidase alfa arm and -1.748 for the agalsidase beta arm (difference -0.749 [-3.026, 1.507]. At month 24, the median slopes for eGFR were -2.514 [-3.788; -1.240] mL/min/1.73 m²/year for the pegunigalsidase alfa arm and -2.155 [-3.805; -0.505] for the agalsidase beta arm
(difference -0.359 [-2.444; 1.726]).
Who knows maybe by the end of the third year mean slopes for eGFR will be equal or the Elfabrio will even act better?